Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ReVance Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

After spending its first three years quietly amassing preclinical and clinical data on its pipeline for aesthetic and therapeutic dermatology, Essentia Biosystems is ready to make some noise. It has unveiled a new name, ReVance Therapeutics Inc., will soon announce some key hires, and is preparing to enter the clinic with its lead candidate, a topical, "wipe-on" form of botulinum toxin delivered with the company's proprietary technology for transporting large molecule drugs through the skin.

You may also be interested in...



Aesthetics: Noninvasive Fat Removal Enters the Scene

New energy-based fat removal technology is emerging as the next frontier in noninvasive energy-based aesthetics, but questions remain as to its mechanism of action in treating fat or cellulite. There is no question that patient demand is strong, and there are a number of products and techniques under development.

Dermatology Start-Ups

Judging from the number of recent well-financed company launches and the size of follow-on rounds for established players, specialty dermatology hasn't lost its allure for investors. Add to that two successful 2004 IPOs--for Barrier Therapeutics Inc. and Cutera Inc.--and it's clear that aesthetic and therapeutic dermatology are still good bases for building specialty pharmaceutical businesses.

In Vivo's Deals Of The Month, February 2018

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel